Trypanosoma cruzi: 4-aminopyrazolopyrimidine in the treatment of experimental Chagas' disease

Experimental Parasitology
J L AvilaH Monzón

Abstract

An allopurinol metabolite, 4-aminopyrazolopyrimidine, was tested on two different strains of mice (NMRI-IVIC and C57Bl/6J) that had been infected 4 days earlier with the virulent Ya strain of Trypanosoma cruzi. Low doses of 4-aminopyrazolopyrimidine (0.125-0.500 mg/kg body wt/day) for 10 days induced a significant reduction in parasitemia (direct counts and subinoculation experiments) and increased survival time (without any evidence of toxicity) compared with untreated animals. When tested in vitro, 4-aminopyrazolopyrimidine was sixfold more active than allopurinol as a trypanostatic drug. The low therapeutic doses of 4-aminopyrazolopyrimidine suggest that this drug may be useful in the treatment of acute Chagas' disease.

References

May 1, 1979·The American Journal of Tropical Medicine and Hygiene·J L AvilaA Avila
Aug 1, 1979·Experimental Parasitology·J L AvilaF Rodríguez
Aug 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·S BalasubramaniamM S Brown
Jun 15, 1975·Biochemical Pharmacology·D J Nelson, G B Elion
Nov 1, 1956·Proceedings of the Society for Experimental Biology and Medicine·F S PHILIPSS S STERNBERG

❮ Previous
Next ❯

Citations

Jan 1, 1987·Comparative Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology·J L AvilaR K Robins
Sep 3, 2003·Pharmacology & Therapeutics·Mahmoud H el Kouni
Mar 1, 1987·Antimicrobial Agents and Chemotherapy·J L AvilaR K Robins
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Mohammed I Al-Salabi, Harry P de Koning
Oct 20, 2010·Drug Design, Development and Therapy·Werner Apt
Mar 31, 2021·Journal of Medicinal Chemistry·Jakob BoutonSerge Van Calenbergh

❮ Previous
Next ❯

Related Concepts